Side Effects
The safety profile of retatrutide is consistent with other incretin-based therapies, with gastrointestinal events being most common:
Common side effects (dose-dependent):
- Nausea (14 to 45% depending on dose)
- Diarrhea (9 to 20%)
- Vomiting (3 to 26%)
- Constipation (7 to 16%)
- Decreased appetite (13 to 31%)
- Fatigue (4 to 12%)
Less common effects:
- Injection site reactions
- Mild increases in heart rate (approximately 6.7 bpm at 12 mg, dose-dependent, peaking at 24 weeks, then declining)
- Dysesthesia / cutaneous hyperesthesia (altered skin sensation): 20.9% at 12 mg vs 0.7% placebo in TRIUMPH-4 Phase 3, typically mild, and did not appear in Phase 2 trials — it emerged only in larger Phase 3 studies. The probable mechanism is glucagon receptor activation in cutaneous sensory neurons, which is unique to retatrutide among incretin-class drugs.
- Transient increases in lipase levels
Serious but rare:
- Acute pancreatitis (1 case in phase 2 trial)
- Hypersensitivity reactions
- Biliary disorders (cholelithiasis, cholecystitis)
“The GI side effect profile mirrors what we see across the incretin class, but the dose-dependent nausea rates reaching 45% at higher doses underscore why structured dose escalation is non-negotiable — starting low and titrating slowly is the single most effective strategy for improving patient tolerability and adherence.”
“Dysesthesia is the safety signal to watch as retatrutide advances through Phase 3. At 20.9% incidence it is not rare, but the vast majority of cases are mild and self-limiting. The key question is whether dose titration strategies or lower maintenance doses can mitigate it without sacrificing efficacy — this will be a central consideration for the NDA submission.”